期刊文献+

加巴喷丁治疗带状疱疹后剧烈神经疼痛76例疗效观察 被引量:5

暂未订购
导出
摘要 目的观察采用大剂量加巴喷丁治疗的带状疱疹后剧烈神经疼痛的效果。方法选择的带状疱疹后剧烈神经疼痛患者76例,随即分为加巴喷丁组(A组)和氨酚羟考酮(泰勒宁)组(B组)。加巴喷丁组:口服加巴喷丁胶囊(派汀)第1天服900mg(3粒,3次/d),第2、3天分别增至1 800mg、2 700mg,第4、5、6天分别增至3 000mg、3 300mg、3 600mg,以后维持3 600mg/d,共21d。氨酚羟考酮(泰勒宁)组:口服泰勒宁1片/6h,连服21d。结果 A组优良率97.5%,B组优良率80.6%。2组治疗效果比较差异具有统计学意义(P<0.01)。结论采用大剂量加巴喷丁治疗带状疱疹后剧烈神经疼痛,效果好、见效快、病人顺应性好、病人满意度高,是理想的治疗方法。
出处 《中国实用神经疾病杂志》 2012年第21期81-83,共3页 Chinese Journal of Practical Nervous Diseases
  • 相关文献

参考文献5

  • 1宋文阁,傅志俭.临床疼痛学[M].3版.济南:山东科技出版社.2004:723-726.
  • 2李杰,燕玮,王晓天.普瑞巴林在带状疱疹后神经痛中的应用[J].实用药物与临床,2011,14(4):340-341. 被引量:13
  • 3Tsavaris N, Kopterides P, Kosmas C, et al. Gabapentin mon- otherapy for the treatment of chemotherapy-induced nearopath- ic pain: a pilot study[J]. Pain Med, 2008, 9(8) : 1 209-1 216.
  • 4Ross JR,Goller K, Hardy J,et al. Gabapentin is effective in the treatment of cancer-related neuropathic pain: a prospective, open-label study[J]. J Palliat Med,2005,8(6):1 118-1 126.
  • 5Gee NS, Brown JP, Dissanaayake VU, et al. The novel anti- convulsant drug, gabapentin (Neurontin), binds to the alphaz delta subunit of a calcium channel[J]. J Biol Chem, 1996,271 (10) :6 768-6 776.

二级参考文献20

  • 1黄文阁,王东华,樊兰华.带状疱疹后神经痛的研究进展[J].现代中西医结合杂志,2006,15(13):1852-1854. 被引量:7
  • 2Pappagallo M, Haldey EJ. Pharmacological management of postherpetic neuralgia [ J ]. CNS Drugs, 2003, 17 ( 11 ) : 771 - 780.
  • 3Collins SL,Moore RA,McQuay HJ,et al. Antidepressants and anticon vulsants for diabetic neuropathy and postherpetic neu- ralgia: a quantitative systematic review[ J ]. J Pain Symtom Manage,2000,20 ( 6 ) :449.
  • 4Daris JL, Smith RL. Painful peripheral diabetic neuropathy treated with venlafaxlne HCL extended release capsules [ J]. Diabetes C, 1999,22 : 1909.
  • 5Tremont-Lukats IW, Megeff C, Backonja MM. Anticonvulsants for neuropathic pain syndromes: mechanisms of action and place in therapy[ J]. Drugs,2000,60(5 ) : 1029-1052.
  • 6Feng R, Koup J, Radulovic L, et al. Pregabalin: pharmacoki- netics, pharmacodynamics and interspecies scaling [ A ]//11 th Annual FDA science Forum FDA Science[ C]. 2005 :A-17.
  • 7Ben-Menachem E. Pregabalin pharmacology and its relevance to clinical practice [ J ]. Epilepsia, 2004,45 ( Suppl 6 ) : S13- S18.
  • 8Pande AC ,Crockatt JG, Feltner DE. et al. 1 'regabalin in gen- eralized anxiety disorder:a placebo-controUed trials[ J ]. Am J Psychiatry ,2003,160( 3 ) :533-540.
  • 9Pohl RB, Feltner DE, Fieve RR, et al. Pregabalin in the treat- ment of generalized anxiety disorder: double-blind, placebo + controlled comparison of BID versus TID dosing [ J ]. J Clin Psychopharmaco1,2005,25 ( 2 ) : 151-158.
  • 10Feltner DE, Crockatt JG, Dubovsky SJ, et al. A randomized, double-blind, placebo-controUed, fixed-dose, multi-center study of pregabalin in patients with generalized anxiety disor- der[ J]. J Clin Psyehopharmacol,2003,23 ( 3 ) :240-249.

共引文献16

同被引文献41

引证文献5

二级引证文献42

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部